Agreement supports commitment to patient access, affordability and innovation –

Astellas Pharma Inc. announced that it has reached an agreement with the U.S. government that reflects our commitment to patient access, affordability and innovation, while reinforcing Astellas' longstanding commitment to the U.S. healthcare system.

Under the agreement, Astellas will take the following actions:

• Lower the prices of medicines in Medicaid and establish pricing for future medicines aligned with other developed nations that reflect international market conditions, innovation, and patient value.

• Further the resilience of the supply chain for important medicines by donating 25 kg of tacrolimus active pharmaceutical ingredient (API), the standard used to prevent solid organ transplant rejection, to the U.S. Strategic Active Pharmaceutical Ingredients Reserve (SAPIR).

Additional terms of the agreement are not being disclosed.

This agreement reflects our longstanding commitment to improving access for patients while continuing to invest in the research and development of innovative medicines.  We believe patients benefit most when affordability and innovation advance together, and we remain committed to working collaboratively with governments and healthcare stakeholders around the world to achieve both objectives for patients with serious unmet medical needs.

With U.S. headquarters in Northbrook, Ill., Astellas has a significant research, manufacturing, and economic footprint in the U.S. that supports patients, jobs and communities spanning from Massachusetts to California. Within the past ten years, Astellas has opened two new cutting-edge manufacturing facilities in the U.S., including a cell therapy manufacturing facility in Westborough, Mass., and a gene therapy manufacturing facility in Sanford, North Carolina. In 2024, Astellas also opened two new research centers – our West Coast Innovation Center in South San Francisco and the Astellas Life Sciences Center in Cambridge, Mass.